Arbutus Biopharma Corporation
ABUS
$3.14
$0.020.64%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.17M | 6.74M | 10.06M | 12.99M | 18.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.17M | 6.74M | 10.06M | 12.99M | 18.14M |
| Cost of Revenue | 54.04M | 62.79M | 68.69M | 70.83M | 73.70M |
| Gross Profit | -47.87M | -56.05M | -58.63M | -57.84M | -55.56M |
| SG&A Expenses | 25.83M | 22.50M | 23.80M | 22.24M | 22.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.87M | 85.29M | 92.49M | 93.06M | 96.18M |
| Operating Income | -73.69M | -78.55M | -82.43M | -80.08M | -78.03M |
| Income Before Tax | -69.92M | -76.70M | -77.09M | -74.39M | -72.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.92 | -76.70 | -77.09 | -74.39 | -72.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.92M | -76.70M | -77.09M | -74.39M | -72.85M |
| EBIT | -73.69M | -78.55M | -82.43M | -80.08M | -78.03M |
| EBITDA | -72.31M | -77.14M | -80.99M | -78.65M | -76.63M |
| EPS Basic | -0.38 | -0.43 | -0.44 | -0.44 | -0.44 |
| Normalized Basic EPS | -0.23 | -0.25 | -0.27 | -0.27 | -0.27 |
| EPS Diluted | -0.38 | -0.43 | -0.44 | -0.44 | -0.44 |
| Normalized Diluted EPS | -0.23 | -0.25 | -0.27 | -0.27 | -0.27 |
| Average Basic Shares Outstanding | 742.37M | 721.25M | 699.77M | 677.79M | 663.81M |
| Average Diluted Shares Outstanding | 742.37M | 721.25M | 699.77M | 677.79M | 663.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
